As BRAFV600E-inhibitors become standard treatment for many metastatic melanoma patients, research has begun to elucidate their impact on the tumor immune landscape. Here, we highlight our recent studies demonstrating the ability of melanoma cell-intrinsic BRAFV600E-inhibition to selectively reduce intratumoral immunosuppressive cell populations and enhance antitumor CD8+ T-cell immunity.
Keywords: BRAF; CD8 T cells; MDSC, myeloid-derived suppressor cell; TME, tumor microenvironment; Treg, regulatory T cell; melanoma; myeloid-derived suppressor cells; regulatory T cells.